重组人血管内皮抑制素的聚集稳定性及其PLGA缓释微球的制备与体外释放
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Stability of rh-endostatin and fabrication/release test of rh-endostatin loaded PLGA microspheres
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:制备重组人血管内皮抑制素(rh-endostatin, rh-Endo)的聚乳酸-羟基乙酸\[poly(lactic-co-glycolic acid),PLGA\]微球,并对微球的体外释放特性进行考察。方法:以聚乳酸-羟基乙酸为载体,采用复乳法制备重组人血管内皮抑制素聚乳酸-羟基乙酸微球,建立了高效液相色谱法测定rh-Endo含量和体外释药量。结果:微球外观圆整,平均粒径122.7 μm,载药量为1.28%,包封率为38.65%,250 μg/ml的rh-Endo标准溶液4℃、室温条件下放置108 h后,溶液仍呈现较好的稳定性。28 d的体外释放可达67.37%。结论:以可生物降解的PLGA作为载体材料,能够将rh-Endo制成缓释微球。

    Abstract:

    Objective:To prepare rh-endostatin loaded poly(lactic-co-glycolic acid)(PLGA)microspheres and to evaluate their release behavior in vitro.Methods: Rh-endostatin PLGA microspheres were prepared by W/O/W process.The content and in vitro cumulative release was determined by a HPLC method.Results: The prepared microspheres were well-shaped, with a mean diameter of 122.7 μm.The drug loading and encapsulation efficiency were 1.28% and 38.65%, respectively.The rh-Endo solution (250 μg/ml) showed good stability after placed at 4℃ and 25℃ for 108 h.The cumulative in vitro release was up to 67.37% in 28 days.Conclusion: The rh-Endo can be encapsulated in microspheres to yield sustained release using biodegradable polymers PLGA as the carrier material.

    参考文献
    相似文献
    引证文献
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2008-07-10
  • 最后修改日期:2008-11-25
  • 录用日期:2008-11-27
  • 在线发布日期: 2009-01-16
  • 出版日期:
文章二维码
重要通知
友情提醒: 近日发现论文正式见刊或网络首发后,有人冒充我刊编辑部名义给作者发邮件,要求添加微信,此系诈骗行为!可致电编辑部核实:021-81870792。
            《海军军医大学学报》编辑部
关闭